• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在肺癌模型中,利用缺氧调节转基因载体增强人制瘤素的抗血管生成作用。

Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model.

作者信息

Li Yu-Ying, Qian Gui-Sheng, Huang Gui-Jun, Chen Feng, Qian Pin, Yu Shi-Cang, Wang Chang-Zheng, Li Qi, Wang Jian-Chun, Wu Guo-Ming

机构信息

Institute of Respiratory Disease, Department of Respiratory Disease, Xinqiao Hospital, The Third Military Medical University, Chongqing, PR China.

出版信息

Cancer J. 2006 Mar-Apr;12(2):136-46.

PMID:16630405
Abstract

UNLABELLED

Canstatin, a newly identified antiangiogenesis protein, has a potent inhibitory effect on the proliferation and growth of endothelial cells. To enhance the expression and antiangiogenic effects of canstatin in solid tumors, we constructed a eukaryotic expression vector that encodes human canstatin cDNA downstream from nine copies of the hypoxia-response element.

METHODS

Canstatin complementary DNA from adult liver tissues was cloned into the mammalian expression vector pCMV-Script. Nine copies of the hypoxia-response element were ligated upstream from the canstatin gene near the cytomegalovirus promoter. The recombinant vector, pCMV9Cans, was transformed into A549 cells by cationic liposomes. The transformed cells were cultured under oxic and anoxic conditions. We detected canstatin messenger ribonucleic acid and protein expression in transformed cells by TaqMan polymerase chain reaction and Western blot analysis, respectively. Human umbilical vein endothelial cells were cocultured with recombinant vector transformed A549 cells using Transwell plates under oxic and anoxic conditions. The proliferation and apoptosis of the cocultured endothelial cells were evaluated with 3H-thymidine incorporation and terminal deoxynucleotidyl-mediated biotinylated deoxyuridine triphosphate nick end-labeling methods (TUNEL), respectively. A canstatin-encoding vector with no hypoxia-response element, pCMVCans, was used as the positive control, and naked plasmid-transformed and singly cultured parental cells were used as negative controls. The biologic activity of the vector in tumor tissues of lung cancer-bearing nude mice was evaluated by microvessel counts. Canstatin protein expression was assessed by Western blot analysis in tumor tissues. pCMVCans and empty vector were used as controls in the in vivo assays.

RESULTS

Canstatin messenger RNA and protein were detected in both pCMV9Cans- and pCMVCans-transformed A549 clones. Under oxic conditions, canstatin expression was not significantly different in clones stably transformed with pCMV9Cans or pCMVCans. However, under anoxic conditions canstatin expression was significantly higher in pCMV9Cans-transformed cells than in pCMVCans-transformed cells. Moreover, the 3H-thymidine uptake rate of the human umbilical vein endothelial cells was markedly lower than that of the pCMVCans-transformed cells, and many endothelial cells underwent apoptosis when cocultured with pCMV9Cans-transformed A549 cells, especially under anoxic conditions. We detected canstatin expression in tumor tissues; the expression level in pCMV9Cans-transformed tumors was significantly higher than that in pCMVCans-transformed tumors. An in vivo assay showed that tumors transformed with pCMV9Cans remained small, and microvessels in those tumors were much fewer than those in pCMVCans-transformed tumors.

CONCLUSION

The hypoxia-regulated vector pCMV9Cans increases the expression of canstatin, thereby enhancing its biological effects. We believe that the hypoxia-inducible canstatin-expressing vector is a promising gene therapy tool for antiangiogenesis research.

摘要

未标记

Canstatin是一种新发现的抗血管生成蛋白,对内皮细胞的增殖和生长具有强大的抑制作用。为增强Canstatin在实体瘤中的表达及抗血管生成作用,我们构建了一种真核表达载体,该载体在九个缺氧反应元件下游编码人Canstatin cDNA。

方法

从成人肝脏组织中克隆Canstatin互补DNA,将其插入哺乳动物表达载体pCMV-Script。在靠近巨细胞病毒启动子的Canstatin基因上游连接九个缺氧反应元件。通过阳离子脂质体将重组载体pCMV9Cans转入A549细胞。将转化后的细胞在有氧和无氧条件下培养。分别通过TaqMan聚合酶链反应和蛋白质免疫印迹分析检测转化细胞中Canstatin信使核糖核酸和蛋白质表达。在有氧和无氧条件下,使用Transwell板将人脐静脉内皮细胞与重组载体转化的A549细胞共培养。分别用3H-胸腺嘧啶核苷掺入法和末端脱氧核苷酸介导的生物素化脱氧尿苷三磷酸缺口末端标记法(TUNEL)评估共培养内皮细胞的增殖和凋亡。将不含缺氧反应元件的Canstatin编码载体pCMVCans用作阳性对照,将裸质粒转化的和单独培养的亲本细胞用作阴性对照。通过微血管计数评估该载体在荷肺癌裸鼠肿瘤组织中的生物学活性。通过蛋白质免疫印迹分析评估肿瘤组织中Canstatin蛋白表达。在体内实验中,将pCMVCans和空载体用作对照。

结果

在pCMV9Cans和pCMVCans转化的A549克隆中均检测到Canstatin信使核糖核酸和蛋白质。在有氧条件下,用pCMV9Cans或pCMVCans稳定转化的克隆中Canstatin表达无显著差异。然而,在无氧条件下,pCMV9Cans转化细胞中的Canstatin表达明显高于pCMVCans转化细胞。此外,人脐静脉内皮细胞的3H-胸腺嘧啶核苷摄取率明显低于pCMVCans转化细胞,并且当与人脐静脉内皮细胞共培养时,许多内皮细胞发生凋亡,尤其是在无氧条件下。我们在肿瘤组织中检测到Canstatin表达;pCMV9Cans转化肿瘤中的表达水平明显高于pCMVCans转化肿瘤。体内实验表明,用pCMV9Cans转化的肿瘤仍然较小,并且这些肿瘤中的微血管比pCMVCans转化肿瘤中的微血管少得多。

结论

缺氧调节载体pCMV9Cans增加了Canstatin的表达,从而增强了其生物学效应。我们认为,缺氧诱导的Canstatin表达载体是抗血管生成研究中一种有前途的基因治疗工具。

相似文献

1
Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model.在肺癌模型中,利用缺氧调节转基因载体增强人制瘤素的抗血管生成作用。
Cancer J. 2006 Mar-Apr;12(2):136-46.
2
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.肿瘤坏死因子相关凋亡诱导配体(TRAIL)与制瘤素基因抑制疗法联合对小鼠乳腺肿瘤异种移植瘤生长的影响
Breast Cancer Res Treat. 2008 Jul;110(2):283-95. doi: 10.1007/s10549-007-9731-4. Epub 2007 Sep 26.
3
[Reconstruction of adenovirus vector contained canstatin gene and hTERT gene core promoter and its anti-tumor effect in human ovarian cancer].[含抑癌蛋白基因和人端粒酶逆转录酶基因核心启动子的腺病毒载体构建及其对人卵巢癌的抗肿瘤作用]
Zhonghua Fu Chan Ke Za Zhi. 2009 Mar;44(3):214-8.
4
[HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].[使用缺氧/辐射双敏感启动子的肺腺癌异种移植瘤单纯疱疹病毒胸苷激酶基因治疗]
Ai Zheng. 2004 Jul;23(7):788-93.
5
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.一种基于血管生成抑制剂血管抑制素的癌症基因疗法。
Gene Ther. 2002 Sep;9(18):1207-13. doi: 10.1038/sj.gt.3301788.
6
The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.Canstatin的C末端结构域可抑制体内与内皮细胞增殖相关的肿瘤生长。
Biochem Biophys Res Commun. 2004 May 28;318(2):354-60. doi: 10.1016/j.bbrc.2004.04.038.
7
Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.通过RNA干扰方法阻断血管内皮生长因子的表达来抑制恶性黑色素瘤的生长。
Br J Dermatol. 2005 Oct;153(4):715-24. doi: 10.1111/j.1365-2133.2005.06765.x.
8
Functional expression of recombinant canstatin in stably transformed Drosophila melanogaster S2 cells.重组制癌蛋白在稳定转化的果蝇S2细胞中的功能表达。
Protein Expr Purif. 2007 Apr;52(2):258-64. doi: 10.1016/j.pep.2006.11.016. Epub 2006 Dec 5.
9
Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.克隆的与tumstatin相关的血管生成抑制肽对内皮细胞增殖和凋亡的影响。
Chin Med J (Engl). 2008 Nov 20;121(22):2324-30.
10
Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.Canstatin-N片段在体外抑制内皮细胞增殖,并在体内抑制肿瘤生长。
Biochem Biophys Res Commun. 2003 Dec 19;312(3):801-5. doi: 10.1016/j.bbrc.2003.11.003.

引用本文的文献

1
Loss of heterozygosity of chromosome 13q33-34 region and molecular analysis of ING1 and p53 genes in bladder carcinoma.膀胱癌中13q33 - 34区域杂合性缺失及ING1和p53基因的分子分析
Mol Biol Rep. 2015 Feb;42(2):507-16. doi: 10.1007/s11033-014-3794-1. Epub 2014 Oct 17.
2
Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease.缺氧调控的视网膜神经胶质细胞特异性启动子在疾病的基因治疗中的应用。
Invest Ophthalmol Vis Sci. 2011 Nov 1;52(12):8562-70. doi: 10.1167/iovs.10-6835.
3
Robust hypoxia-selective regulation of a retinal pigment epithelium-specific adeno-associated virus vector.
视网膜色素上皮特异性腺相关病毒载体的强大低氧选择性调控
Mol Vis. 2008 Mar 7;14:471-80.